[144] Adaptimmune Therapeutics plc American SEC Filing

Rhea-AI Filing Summary

Adaptimmune Therapeutics plc (ADAP) Form 144 notice reports a proposed sale of 34,500 American Depositary Shares (ADS) executed through ETrade by Morgan Stanley with an approximate sale date of 08/28/2025 on Nasdaq. The filing shows an aggregate market value of $2,070 for the shares and lists 256,032,610 shares outstanding. The securities were acquired in an open-market purchase on 12/14/2020 for cash by the person filing, and no securities were reported sold in the prior three months. Several filer and issuer identification fields in the document are left blank in the provided content.

Positive

• Disclosure provided under Rule 144 indicating transparency about a proposed sale
• Acquisition was an open-market purchase paid in cash, simplifying provenance of the shares
• No securities sold in prior three months, reducing aggregation complexity for Rule 144 calculations

Negative

• Key filer and issuer identification fields are missing or not provided in the supplied content, limiting traceability
• Aggregate market value reported ($2,070) is extremely small relative to the stated outstanding shares, suggesting immateriality to capitalization

Insights

Securities Analyst

Small, routine insider sale notice with no clear material effect on capitalization.

The filing documents a proposed sale of 34,500 ADS purchased in 2020 and held for several years. The stated aggregate market value in the notice is $2,070 and the issuer's outstanding share count is listed as 256,032,610. Based on those figures, this appears to be a routine Rule 144 notice rather than a transaction likely to materially affect the company's capitalization or liquidity. The filing lacks identifying filer CIK and issuer contact details in the provided content, which limits assessment of the seller's role (e.g., officer, director or large holder).

Compliance / Risk Analyst

Compliance disclosure appears standard but the record has missing identifying details.

The form includes the required representations about absence of undisclosed material information and indicates cash payment at acquisition. It also states no sales in the prior three months. However, key filer and issuer identification fields are blank in the supplied text, which is important for tracing regulatory compliance and aggregation obligations. From a risk perspective, the notice itself raises no new regulatory red flags based on the content shown.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares	ETrade by Morgan Stanley 200 Hudson Street, Suite 501 New Jersey NJ 07311	34500	2070.00	256032610	08/28/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
American Depositary Shares	12/14/2020	Open market purchase	Not known			34500	12/14/2020	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for ADAP announce?

The form notifies a proposed sale of 34,500 ADS on Nasdaq with an approximate sale date of 08/28/2025.

How were the ADS acquired according to the filing?

The ADS were acquired in an open-market purchase on 12/14/2020 and paid for in cash.

What is the aggregate market value and outstanding share count listed?

The filing lists an aggregate market value of $2,070 for the proposed sale and 256,032,610 shares outstanding.

Were any shares of ADAP sold by the filer in the prior three months?

The filing states Nothing to Report for securities sold during the past three months.

Does the filing include required compliance representations?

Yes, it includes the representation that the seller does not know of any undisclosed material adverse information and references Rule 10b5-1 plan language.